Title
Category
Credits
Event date
Cost
  • CMHC
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Patient with ILDs, especially those with a progressive fibrosis phenotype, maybe at a greater risk for having worse outcomes with COVID-19, including during and post-COVID-19 infection. However, the management of patients with PF-ILDs and COVID-19 is not clear, including the potential management of COVID-19 related lung injury and fibrosis, as well as the overall management of ILDs in the COVID-19 era. During this webcast, experts will discuss these gaps and the implications of COVID-19 in the management of patients with ILDs and PF-ILD.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The treatment of Atopic Dermatitis (AD) is a clinical challenge. Current treatment regimens are not curative, and patients and caregivers are frequently dissatisfied with and poorly adherent to treatment (O’Toole 2013; Snyder 2015).  The chronic nature of AD demands that clinicians be able to create flexible long-term treatment plans that evolve according to patient need. As more is understood about the disease, it has become apparent that not all forms of AD are epidemiologically and/or clinically equal (Malajian 2015).
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Psoriasis is a chronic and inflammatory skin disease with potential systemic implications that affects 7.5 million people in the United States (Bhushan 2016; Soleymani 2018) that can lead to several comorbidities, including psoriatic arthritis, obesity, metabolic syndrome, and cardiovascular disease (Soleymani 2018). Early diagnosis and treatment are crucial in managing PsA, and clinicians need to understand the impact of both skin and joint aspects of psoriasis and PsA in order to minimize impact on patients’ quality of life (QOL).
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in atopic dermatitis presented at the 29th Annual Masters of Pediatric Dermatology and the 19th Annual South Beach Symposium.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in psoriasis presented at the 29th Annual Masters of Pediatric Dermatology and the 19th Annual South Beach Symposium.
  • LivDerm
  • TME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
Acne is a chronic and inflammatory skin disorder that affects up to 50 million individuals in the United States and is one of the most common dermatologic conditions in children and adolescents (Lim 2017; Nagler 2016). Acne is characterized by noninflammatory lesions (open and closed comedones) and inflammatory lesions (papules, pustules, and nodules). The pathogenic mechanisms include microbial colonization with Propionibacterium acnes (P acnes), sebum production, inflammatory mechanisms, and follicular hyperkeratinization (Eichenfield 2013).
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Acne Vulgaris presented at the 28th Annual Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium.
  • LivDerm
  • TME
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
This course will provide you with valuable updates in Atopic Dermatitis presented at the 28th Annual Masters of Pediatric Dermatology and the 18th Annual South Beach Symposium.
  • LivDerm
  • TME
  • AAPA Category I CME
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
There are gaps in dermatologic care today concerning patients with skin of color (SOC) that need to be addressed through education and putting new knowledge into practice. Patients with SOC can be disproportionately affected by dermatologic conditions such as melasma, acne, rosacea, and hyperpigmentation. Even children with SOC can be more susceptible or have a greater disease burden, especially with conditions such as acne, vitiligo, atopic dermatitis, keloids, pityriasis alba, and traction alopecia.
  • LivDerm
  • TME
  • AAPA Category I CME
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
The increasing incidence of Atopic dermatitis (AD) and poor recognition of the disease in some patient groups is a public health concern. AD symptoms and its daily management cause significant effects on quality of life for both patients and caregivers. AD is associated with an increase in other atopic manifestations as well as with serious comorbidities that can greatly affect overall patient health and wellbeing (Silverberg 2015; Simpson 2012; Yu 2016; Zheng 2011).

Pages